<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Basic Res Cardiol</journal-id><journal-title-group><journal-title>Basic Research in Cardiology</journal-title></journal-title-group><issn pub-type="ppub">0300-8428</issn><issn pub-type="epub">1435-1803</issn><publisher><publisher-name>D. Steinkopff-Verlag</publisher-name><publisher-loc>Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">53</article-id><article-id pub-id-type="doi">10.1007/s00395-009-0053-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Contribution</subject></subj-group></article-categories><title-group><article-title>Protein kinase C &#x003b1; and &#x003b5; phosphorylation of troponin and myosin binding protein C reduce Ca<sup>2+</sup> sensitivity in human myocardium</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kooij</surname><given-names>Viola</given-names></name><address><phone>+31-20-4448124</phone><fax>+31-20-4448255</fax><email>v.kooij@vumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Boontje</surname><given-names>Nicky</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zaremba</surname><given-names>Ruud</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jaquet</surname><given-names>Kornelia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>dos Remedios</surname><given-names>Cris</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Stienen</surname><given-names>Ger J. M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>van der Velden</surname><given-names>Jolanda</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands </aff><aff id="Aff2"><label>2</label>Forschungslabor Molekulare Kardiologie, St. Josef Hospital/Bergmannsheil, Kliniken der Ruhr-Universit&#x000e4;t, Bochum, Germany </aff><aff id="Aff3"><label>3</label>Muscle Research Unit, Institute for Biomedical Research, The University of Sydney, Sydney, Australia </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>8</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>8</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2010</year></pub-date><volume>105</volume><issue>2</issue><fpage>289</fpage><lpage>300</lpage><history><date date-type="received"><day>27</day><month>4</month><year>2009</year></date><date date-type="rev-recd"><day>20</day><month>7</month><year>2009</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2009</copyright-statement></permissions><abstract xml:lang="en"><p>Previous studies indicated that the increase in protein kinase C (PKC)-mediated myofilament protein phosphorylation observed in failing myocardium might be detrimental for contractile function. This study was designed to reveal and compare the effects of PKC&#x003b1;- and PKC&#x003b5;-mediated phosphorylation on myofilament function in human myocardium. Isometric force was measured at different [Ca<sup>2+</sup>] in single permeabilized cardiomyocytes from failing human left ventricular tissue. Activated PKC&#x003b1; and PKC&#x003b5; equally reduced Ca<sup>2+</sup> sensitivity in failing cardiomyocytes (&#x00394;pCa<sub>50</sub>&#x000a0;=&#x000a0;0.08&#x000a0;&#x000b1;&#x000a0;0.01). Both PKC isoforms increased phosphorylation of troponin I- (cTnI) and myosin binding protein C (cMyBP-C) in failing cardiomyocytes. Subsequent incubation of failing cardiomyocytes with the catalytic subunit of protein kinase A (PKA) resulted in a further reduction in Ca<sup>2+</sup> sensitivity, indicating that the effects of both PKC isoforms were not caused by cross-phosphorylation of PKA sites. Both isozymes showed no effects on maximal force and only PKC&#x003b1; resulted in a modest significant reduction in passive force. Effects of PKC&#x003b1; were only minor in donor cardiomyocytes, presumably because of already saturated cTnI and cMyBP-C phosphorylation levels. Donor tissue could therefore be used as a tool to reveal the functional effects of troponin T (cTnT) phosphorylation by PKC&#x003b1;. Massive dephosphorylation of cTnT with alkaline phosphatase increased Ca<sup>2+</sup> sensitivity. Subsequently, PKC&#x003b1; treatment of donor cardiomyocytes reduced Ca<sup>2+</sup> sensitivity (&#x00394;pCa<sub>50</sub>&#x000a0;=&#x000a0;0.08&#x000a0;&#x000b1;&#x000a0;0.02) and solely increased phosphorylation of cTnT, but did not affect maximal and passive force. PKC&#x003b1;- and PKC&#x003b5;-mediated phosphorylation of cMyBP-C and cTnI as well as cTnT decrease myofilament Ca<sup>2+</sup> sensitivity and may thereby reduce contractility and enhance relaxation of human myocardium.</p></abstract><kwd-group><title>Keywords</title><kwd>Protein kinase C</kwd><kwd>Cardiac</kwd><kwd>Heart failure</kwd><kwd>Myofilament function</kwd><kwd>Contractile proteins</kwd><kwd>Phosphorylation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2010</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>The protein kinase C (PKC) family consists of a number of different isozymes with different substrate specificities [<xref ref-type="bibr" rid="CR16">16</xref>]. In the failing human heart PKC activity and the expression of the Ca<sup>2+</sup> dependent isoform PKC&#x003b1; are increased [<xref ref-type="bibr" rid="CR6">6</xref>]. PKC&#x003b1; has been shown to play an important role in the development of cardiac hypertrophy and heart failure [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. PKC&#x003b1; directly phosphorylates regulatory myofilament proteins such as cardiac troponin I (cTnI) and cardiac troponin T (cTnT) [<xref ref-type="bibr" rid="CR17">17</xref>]. PKC&#x003b1; also phosphorylates protein phosphatase inhibitor 1, which alters the activity of protein phosphatase 1 [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. PKC&#x003b5; is another (Ca<sup>2+</sup> independent) PKC isoform, which translocates upon activation to the myofilaments (and the sarcolemma) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Several myofilament regulatory proteins [myosin binding protein C (cMyBP-C), cTnT, cTnI] serve as targets for PKC&#x003b5; [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Moreover, transgenic mice overexpressing constitutively active PKC&#x003b5; slowly develop dilated cardiomyopathy with failure [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Studies in rodent myocardium indicated that cTnT and cTnI phosphorylation influence Ca<sup>2+</sup> sensitivity and were involved in the PKC-mediated depression of the maximal force generating capacity [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Using an in vitro motility assay, an association was observed between the increased PKC expression in failing human hearts and a reduction of the force exerted on thin filaments [<xref ref-type="bibr" rid="CR29">29</xref>]. Moreover, a recent study using two different animal models of congestive heart failure, in which PKC&#x003b1; expression and activation was considerably increased, provided evidence that augmented PKC&#x003b1;-induced myofilament protein phosphorylation contributes to myofilament dysfunction by a reduction of maximum force and of Ca<sup>2+</sup> sensitivity [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p>The expression of the different PKC isoforms, with different substrate specificity, varies between rodents and humans and with different disease states [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. This may affect the basal phosphorylation status of the myocardium and thus influence the effects of the kinases on Ca<sup>2+</sup> sensitivity and force development per se. Specific information on the impact of the different PKC isoforms on contractile function in human myocardium is lacking. Therefore, we investigated the impact of PKC&#x003b1; and PKC&#x003b5; in human tissue from donor and end-stage failing hearts obtained during transplant surgery.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Human ventricular tissue</title><p>Left ventricular (LV) transmural tissue samples were obtained during heart transplantation surgery from ten patients with end-stage dilated cardiomyopathy (NYHA IV) and four non-failing donor hearts (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The tissue was collected in cardioplegic solution and stored in liquid nitrogen. Samples were obtained after informed consent and with approval of the local Ethical Committee (St Vincents&#x02019; Hospital Human Research Ethics Committee: File number: H03/118; Title: Molecular Analysis of Human heart Failure). The investigation conforms with the principles outlined in the Declaration of Helsinki (Cardiovascular Research 1997;35:2&#x02013;4).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Characteristics from donors and patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Sex</th><th align="left">Age</th><th align="left">LVEF (%)</th><th align="left">Medication</th></tr></thead><tbody><tr><td align="left">Donor 1</td><td align="left">Female</td><td char="." align="char">24</td><td char="." align="char">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Donor 2</td><td align="left">Male</td><td char="." align="char">13</td><td char="." align="char">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Donor 3</td><td align="left">Male</td><td char="." align="char">21</td><td char="." align="char">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Donor 4</td><td align="left">Female</td><td char="." align="char">38</td><td char="." align="char">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Patient 1</td><td align="left">Female</td><td char="." align="char">41</td><td char="." align="char">&#x02013;</td><td align="left">ACEI, Diu</td></tr><tr><td align="left">Patient 2</td><td align="left">Female</td><td char="." align="char">45</td><td char="." align="char">8</td><td align="left">ACEI, Diu, &#x003b2;</td></tr><tr><td align="left">Patient 3</td><td align="left">Male</td><td char="." align="char">65</td><td char="." align="char">&#x02013;</td><td align="left">ACEI,Diu</td></tr><tr><td align="left">Patient 4</td><td align="left">Male</td><td char="." align="char">61</td><td char="." align="char">12</td><td align="left">ACEI, Amio, Diu, &#x003b2;</td></tr><tr><td align="left">Patient 5</td><td align="left">Male</td><td char="." align="char">55</td><td char="." align="char">15</td><td align="left">ACEI, Diu</td></tr><tr><td align="left">Patient 6</td><td align="left">Male</td><td char="." align="char">56</td><td char="." align="char">15</td><td align="left">ACEI, Diu, &#x003b2;</td></tr><tr><td align="left">Patient 7</td><td align="left">Male</td><td char="." align="char">56</td><td char="." align="char">20</td><td align="left">ACEI,Diu,&#x003b2;</td></tr><tr><td align="left">Patient 8</td><td align="left">Male</td><td char="." align="char">27</td><td char="." align="char">&#x02013;</td><td align="left">ATII, Diu</td></tr><tr><td align="left">Patient 9</td><td align="left">Female</td><td char="." align="char">23</td><td char="." align="char">15</td><td align="left">ACEI, Diu, &#x003b2;</td></tr><tr><td align="left">Patient 10</td><td align="left">Female</td><td char="." align="char">65</td><td char="." align="char">14</td><td align="left">ACEI, Diu</td></tr></tbody></table><table-wrap-foot><p><italic>LVEF</italic> left ventricular ejection fraction, <italic>ACEI</italic> angiotensin-converting-enzyme inhibitors, <italic>ATII</italic> angiotensin II receptor antagonist, <italic>Amio</italic> amiodarone, <italic>Diu</italic> diuretics, <italic>&#x003b2;</italic> beta-blocker</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Force measurements</title><p>Cardiomyocytes were mechanically isolated, Triton X-100 permeabilized and mounted in the experimental set-up at a sarcomere length of 2.2&#x000a0;&#x003bc;m. Force measurements and maximal rate of force redevelopment measurements were performed as described previously [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>].</p><p>Briefly, a single cardiomyocyte was mounted between a force transducer and piezoelectric motor. After transferring the cardiomyocyte from relaxing solution (5.89&#x000a0;mM Na<sub>2</sub>ATP, 6.48&#x000a0;mM MgCl<sub>2</sub>, 40.76&#x000a0;mM propionic acid (Kprop), 100&#x000a0;mM Bis-2-aminoethanesulfonic acid (BES), 7.0&#x000a0;mM ethylene glycol tetra acetic acid (EGTA), 14.5&#x000a0;mM phosphocreatine disodium salt (CrP), pH 7.10 at 15&#x000b0;C, pCa 9) to activating solution (5.97&#x000a0;mM Na<sub>2</sub>ATP, 6.28&#x000a0;mM MgCl<sub>2</sub>, 40.64&#x000a0;mM Kprop, 100&#x000a0;mM BES, 7.0&#x000a0;mM CaEGTA, 14.5&#x000a0;mM CrP, pH 7.10 at 15&#x000b0;C, pCa 4.5), isometric force was measured. After reaching steady force, the cardiomyocyte was 20% reduced in length within 2&#x000a0;ms and restretched after 30&#x000a0;ms (slack test). During this slack test, force first dropped to zero and after the restretch quickly redeveloped to the original steady state level. A single exponential was fitted to estimate the rate constant of force redevelopment at maximal activation (<italic>K</italic><sub>tr</sub>-max). Calcium sensitivity (pCa<sub>50</sub>) was determined by measuring force in activating solutions with submaximal [Ca<sup>2+</sup>] (pCa values ranged from 5.0 to 6.0) obtained by appropriate mixing of the activating and relaxing solutions. The initial control force at maximal [Ca<sup>2+</sup>] (i.e., pCa 4.5) was used to calculate the maximal force per cross-sectional area. The force values at submaximal [Ca<sup>2+</sup>] were normalized to the interpolated control values [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p>After the initial force-pCa series, the myocyte was incubated for 60&#x000a0;min at 20&#x000b0;C in a Ca<sup>2+</sup>-containing solution (pCa 5.9) containing 6&#x000a0;mM dithiothreitol (DTT), 1&#x000a0;&#x003bc;M PMA (phorbol 12-myristate 13-acetate; Sigma), 50 nM calyculin A (calA, Sigma) without kinase (time control), with 10&#x000a0;&#x003bc;g/mL human recombinant PKC&#x003b1; (Sigma P1782; batch 93K0330) or 10&#x000a0;&#x003bc;g/mL human recombinant PKC&#x003b5; (Sigma P1164; batch 060K1890). CalA was added to the incubation buffer to prevent protein dephosphorylation during incubation. The concentrations of the active PKC isoforms were saturating as no further effect on cardiomyocyte function were seen when the concentration was doubled. A separate group of failing myocytes was incubated for 40&#x000a0;min at 20&#x000b0;C in relaxing solution (see above) containing 6&#x000a0;mM DTT and 100&#x000a0;U/mL of the catalytic subunit of protein kinase A (PKA, Sigma P2645; batch 35H9522). After the incubation the force-pCa series was repeated. A third force-pCa series was performed to study sequential effects, i.e., PKC isoforms after PKA or visa versa.</p><p>The effect of PKC&#x003b1; was also investigated upon pretreatment of failing and donor cardiomyocytes with alkaline phosphatase (AP, calf intestinal, New England Biolabs; 2,000&#x000a0;U/mL) in relaxing solution (pCa 9) containing 6&#x000a0;mM DTT and 50&#x000a0;&#x003bc;L/mL protease inhibitor cocktail (PIC, Sigma, P8340) for 60&#x000a0;min at 20&#x000b0;C. All force measurements were performed at 15&#x000b0;C.</p></sec><sec id="Sec5"><title>Protein analysis</title><sec id="Sec6"><title>Endogenous protein phosphorylation</title><p>To preserve the endogenous phosphorylation status, frozen tissue samples (~1&#x000a0;mg dry weight) were homogenized in liquid nitrogen and resuspended in 1&#x000a0;mL cold (&#x02212;20&#x000b0;C) 10% trichloroacetic acid solution (TCA; dissolved in acetone containing 0.1% (w/v) DTT) [<xref ref-type="bibr" rid="CR27">27</xref>]. Tissue homogenates were kept for 1&#x000a0;h at &#x02212;80&#x000b0;C and slowly heated to room temperature by stepwise increments in temperature as follows: 20&#x000a0;min at &#x02212;20&#x000b0;C, 20&#x000a0;min at 4&#x000b0;C and 20&#x000a0;min at room temperature (20&#x000a0;&#x000b1;&#x000a0;2&#x000b0;C). The homogenates were thoroughly mixed on a vortex between all steps. Thereafter, the tissue homogenates were centrifuged at 12,000<italic>g</italic> for 15&#x000a0;min and tissue pellets were washed with 1&#x000a0;mL of 0.2% (w/v) DTT-acetone solution and shaken for 5&#x000a0;min at room temperature. Centrifugation, washing and shaking was repeated three times. Thereafter tissue pellets were freeze-dried and homogenized in 1D-sample buffer containing 15% glycerol, 62.5&#x000a0;mM Tris (pH 6.8), 1% (w/v) SDS and 2% (w/v) DTT (final concentration 2.5&#x000a0;&#x003bc;g dry weight/&#x003bc;L). To determine basal phosphorylation status of myofilament proteins, myocardial samples (TCA treated 20&#x000a0;&#x003bc;g/lane) were separated on gradient gels (Criterion Tris&#x02013;HCl 4&#x02013;15% gel, BioRad) and stained with Pro-Q diamond phosphoprotein gel stain (Pro-Q; Molecular Probes) in conjunction with SYPRO Ruby staining (Molecular Probes) of the gels [<xref ref-type="bibr" rid="CR43">43</xref>]. The phosphorylation signals for myofilament proteins were normalized to the intensities of the SYPRO Ruby-stained myosin binding protein C (cMyBP-C) bands. All signals were quantified using the luminescent image analyzer LAS-3000 (Fuji Science Imaging Systems) and Aida image analyzer software (Isotopenme&#x003b2;ger&#x000e4;te GmbH, Staubenhardt, Germany).</p></sec><sec id="Sec7"><title>Alterations in myofilament protein phosphorylation</title><p>To investigate the effect of the PKC isoforms as well as of PKA and AP on myofilament protein phosphorylation 600&#x000a0;&#x003bc;g (dry weight) of tissue was treated in with Triton X-100 (0.5%) in relaxing solution (pCa 9) containing PIC (5&#x000a0;&#x003bc;L/mL), phosphatase inhibitor cocktail (PhIC2, Sigma, P5726, 5&#x000a0;&#x003bc;L/mL) and calA (50&#x000a0;nM) for 5&#x000a0;min at room temperature, washed twice with relaxing solution without Triton X-100 and subsequently incubated for 60&#x000a0;min (or 40&#x000a0;min for PKA) at 20&#x000b0;C in 100&#x000a0;&#x003bc;L of (1) relaxing solution containing PIC (50&#x000a0;&#x003bc;L/mL), PhIC2 (50&#x000a0;&#x003bc;L/mL), calA (50 nM) and DTT (6&#x000a0;mM)(=control incubation); (2) activating solution (pCa 5.9) containing PIC (50&#x000a0;&#x003bc;L/mL), PhIC2 (50&#x000a0;&#x003bc;L/mL), calA (50&#x000a0;nM), DTT (6&#x000a0;mM), PMA (1&#x000a0;&#x003bc;M) and PKC&#x003b1; (10&#x000a0;&#x003bc;g/mL) or (3) PKC&#x003b5; (10&#x000a0;&#x003bc;g/mL); (4) relaxing solution containing PIC (50&#x000a0;&#x003bc;L/mL), PhIC2 (50&#x000a0;&#x003bc;L/mL), calA (50&#x000a0;nM), DTT (6&#x000a0;mML) and PKA (100 U/mL); (5) relaxing solution containing PIC (50&#x000a0;&#x003bc;L/mL), DTT (6&#x000a0;mM) and AP (2,000&#x000a0;U/mL). Part of the tissue treated with AP was washed and subsequently incubated with PKC&#x003b1; (see incubation no. 2). Subsequently, tissue was treated with TCA and analyzed using ProQ-stained gradient gels as described above.</p><p>To investigate the effect of PKC&#x003b1; phosphorylation of titin, tissue samples with a final concentration of ~10&#x000a0;&#x003bc;g/&#x003bc;L dry weight were homogenized in 100-150&#x000a0;&#x003bc;L sample buffer consisting of 0.55&#x000a0;M Tris HCL, 0.55&#x000a0;M EDTA, 10% glycerol, 1% &#x003b2;-mercaptoethanol, 20% (w/v) SDS, 8&#x000a0;&#x003bc;L/mL leupeptin (Peptin-institute, Japan), 10&#x000a0;&#x003bc;L/mL PhIC1 (Sigma, P2850) and PhIC2, pH6.8. Myocardial samples (~100&#x000a0;&#x003bc;g/lane) were separated on agarose strengthened 2% sodium dodecyl sulfate-polyacrylamide gels and stained with Pro-Q diamond phosphoprotein gel stain in conjunction with Sypro Ruby staining [<xref ref-type="bibr" rid="CR5">5</xref>]. Staining and analysis as described above.</p></sec></sec><sec id="Sec8"><title>Data analysis</title><p>Force-pCa relations were fit to the Hill equation as described previously [<xref ref-type="bibr" rid="CR37">37</xref>]. Values are given as mean&#x000a0;&#x000b1;&#x000a0;SEM of <italic>n</italic> experiments. Cardiomyocyte force values for donor and failing samples were compared using an unpaired Student <italic>t</italic> test. Effects of incubations without or with PKC&#x003b1;, PKC&#x003b5;, PKA or AP were tested with paired Student <italic>t</italic> test. Repeated measures ANOVA followed by a Bonferroni post hoc test was used when studying the effects of sequential incubations with the PKC isoforms, PKA or AP. <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 was considered significant.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>PKC&#x003b1; and PKC&#x003b5; phosphorylation of cTnI and cMyBP-C decrease Ca<sup>2+</sup> sensitivity in failing myocardium</title><p>Direct incubation of the cardiomyocytes from failing hearts with saturating amounts of PKC&#x003b1; (<italic>n</italic>&#x000a0;=&#x000a0;14 cardiomyocytes) and PKC&#x003b5; (<italic>n</italic>&#x000a0;=&#x000a0;7 cardiomyocytes) resulted in a decrease in Ca<sup>2+</sup> sensitivity (pCa<sub>50</sub>) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a, b). Both PKC isoforms had no effect on maximal force (<italic>F</italic><sub>max</sub>). Passive force (<italic>F</italic><sub>pas</sub>) was reduced after PKC&#x003b1; treatment, whereas PKC&#x003b5; had no significant effect on <italic>F</italic><sub>pas</sub> (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>a). <italic>F</italic><sub>max</sub>, <italic>F</italic><sub>pas</sub> and pCa<sub>50</sub> did not change in the absence of kinases (time control; <italic>n</italic>&#x000a0;=&#x000a0;6 failing cardiomyocytes), while the steepness of the force-pCa relationship (nH) slightly decreased (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>a).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Effect of PKC&#x003b1; end &#x003b5; phosphorylation of myofilament protein on Ca<sup>2+</sup> sensitivity in failing myocardium. Ca<sup>2+</sup> sensitivity of force was significantly decreased in failing cardiomyocytes after incubation with both PKC&#x003b1; (<italic>n</italic>&#x000a0;=&#x000a0;14) (<bold>a</bold>) and PKC&#x003b5; (<italic>n</italic>&#x000a0;=&#x000a0;7) (<bold>b</bold>). The shifts in the mid-points of the curves (&#x00394;pCa<sub>50</sub>) were very similar. Maximum force at saturating Ca<sup>2+</sup> concentration was not affected. <bold>c</bold> Sypro and ProQ stained 1D gels of failing tissue samples incubated without kinases (C) <bold>d</bold> Effect of incubation of PKC&#x003b1; and PKC&#x003b5; on phosphorylation of recombinant troponin complex in comparison to control incubation (C) and basal endogenous phosphorylation of cTnT and cTnI in a failing (F) sample. <italic>Upper panel</italic> Sypro staining. <italic>Lower panel</italic> ProQ staining. <italic>MHC</italic> myosin heavy chain, <italic>PM</italic> peppermintStick phosphoprotein marker (Molecular Probes). <bold>e</bold> Phosphorylation of myofilament proteins was expressed relative to the Sypro Ruby-stained cMyBP-C bands to correct for differences in protein loading. PKC&#x003b1; (<italic>n</italic>&#x000a0;=&#x000a0;5) and PKC&#x003b5; (<italic>n</italic>&#x000a0;=&#x000a0;2) both significantly increased phosphorylation of endogenous myosin binding protein C (cMyBP-C) and troponin I (cTnI), while effects on desmin and troponin T (cTnT) were only small. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, PKC treatment versus control incubation in paired <italic>t</italic> test</p></caption><graphic xlink:href="395_2009_53_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Overview of the force measurements with PKC&#x003b1;, PKC&#x003b5; and PKA incubations (a) and AP and PKC&#x003b1; incubations (b)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Incubation</th><th align="left" colspan="5">Cardiomyocyte measurements</th></tr><tr><th align="left"><italic>F</italic><sub>max</sub></th><th align="left"><italic>F</italic><sub>pas</sub></th><th align="left">pCa<sub>50</sub></th><th align="left">nH</th><th align="left"><italic>K</italic><sub>tr</sub>-max (s<sup>&#x02212;1</sup>)</th></tr></thead><tbody><tr><td align="left" colspan="6">(a)</td></tr><tr><td align="left">PKC&#x003b1;</td><td align="left" colspan="5">7 failing hearts; 14 myocytes</td></tr><tr><td align="left">Before</td><td align="left">28.2&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="left">1.5&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">5.67&#x000a0;&#x000b1;&#x000a0;0.03</td><td align="left">3.43&#x000a0;&#x000b1;&#x000a0;0.18</td><td align="left">0.69&#x000a0;&#x000b1;&#x000a0;0.03</td></tr><tr><td align="left">After</td><td align="left">28.6&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="left">1.4&#x000a0;&#x000b1;&#x000a0;0.2*</td><td align="left">5.59&#x000a0;&#x000b1;&#x000a0;0.03*</td><td align="left">3.28&#x000a0;&#x000b1;&#x000a0;0.24</td><td align="left">0.81&#x000a0;&#x000b1;&#x000a0;0.04*</td></tr><tr><td align="left">PKC&#x003b5;</td><td align="left" colspan="5">5 failing hearts; 7 myocytes</td></tr><tr><td align="left">Before</td><td align="left">30.3&#x000a0;&#x000b1;&#x000a0;3.9</td><td align="left">1.6&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">5.68&#x000a0;&#x000b1;&#x000a0;0.03</td><td align="left">3.86&#x000a0;&#x000b1;&#x000a0;0.20</td><td align="left">0.60&#x000a0;&#x000b1;&#x000a0;0.05</td></tr><tr><td align="left">After</td><td align="left">31.2&#x000a0;&#x000b1;&#x000a0;3.1</td><td align="left">1.4&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">5.60&#x000a0;&#x000b1;&#x000a0;0.02*</td><td align="left">3.42&#x000a0;&#x000b1;&#x000a0;0.13</td><td align="left">0.74&#x000a0;&#x000b1;&#x000a0;0.05*</td></tr><tr><td align="left">PKA</td><td align="left" colspan="5">7 failing hearts; 14 myocytes</td></tr><tr><td align="left">Before</td><td align="left">22.8&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="left">1.4&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">5.65&#x000a0;&#x000b1;&#x000a0;0.02</td><td align="left">3.34&#x000a0;&#x000b1;&#x000a0;0.07</td><td align="left">0.68&#x000a0;&#x000b1;&#x000a0;0.02</td></tr><tr><td align="left">After</td><td align="left">22.9&#x000a0;&#x000b1;&#x000a0;2.0</td><td align="left">1.4&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="left">5.53&#x000a0;&#x000b1;&#x000a0;0.01*</td><td align="left">3.57&#x000a0;&#x000b1;&#x000a0;0.13*</td><td align="left">0.84&#x000a0;&#x000b1;&#x000a0;0.04*</td></tr><tr><td align="left">Control<sup>#</sup></td><td align="left" colspan="5">2 failing hearts; 6 myocytes</td></tr><tr><td align="left">Before</td><td align="left">22.7&#x000a0;&#x000b1;&#x000a0;2.5</td><td align="left">1.5&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="left">5.66&#x000a0;&#x000b1;&#x000a0;0.03</td><td align="left">3.16&#x000a0;&#x000b1;&#x000a0;0.12</td><td align="left">0.64&#x000a0;&#x000b1;&#x000a0;0.06</td></tr><tr><td align="left">After</td><td align="left">22.1&#x000a0;&#x000b1;&#x000a0;2.5</td><td align="left">1.3&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="left">5.67&#x000a0;&#x000b1;&#x000a0;0.03</td><td align="left">2.65&#x000a0;&#x000b1;&#x000a0;0.11*</td><td align="left">0.74&#x000a0;&#x000b1;&#x000a0;0.04</td></tr><tr><td align="left" colspan="6">(b)</td></tr><tr><td align="left">AP</td><td align="left" colspan="5">5 failing hearts; 11 myocytes</td></tr><tr><td align="left">Before</td><td align="left">35.7&#x000a0;&#x000b1;&#x000a0;3.6</td><td align="left">1.8&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">5.64&#x000a0;&#x000b1;&#x000a0;0.02</td><td align="left">3.68&#x000a0;&#x000b1;&#x000a0;0.11</td><td align="left">0.76&#x000a0;&#x000b1;&#x000a0;0.07</td></tr><tr><td align="left">After</td><td align="left">38.6&#x000a0;&#x000b1;&#x000a0;4.5*</td><td align="left">2.5&#x000a0;&#x000b1;&#x000a0;0.3*</td><td align="left">5.73&#x000a0;&#x000b1;&#x000a0;0.03*</td><td align="left">2.85&#x000a0;&#x000b1;&#x000a0;0.13*</td><td align="left">0.68&#x000a0;&#x000b1;&#x000a0;0.04</td></tr><tr><td align="left">AP&#x000a0;+&#x000a0;PKC&#x003b1;</td><td align="left" colspan="5">5 failing hearts; 10 myocytes</td></tr><tr><td align="left">Before</td><td align="left">35.5&#x000a0;&#x000b1;&#x000a0;3.8</td><td align="left">2.6&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">5.73&#x000a0;&#x000b1;&#x000a0;0.03</td><td align="left">2.84&#x000a0;&#x000b1;&#x000a0;0.14</td><td align="left">0.56&#x000a0;&#x000b1;&#x000a0;0.06</td></tr><tr><td align="left">After</td><td align="left">35.1&#x000a0;&#x000b1;&#x000a0;3.9</td><td align="left">2.4&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="left">5.60&#x000a0;&#x000b1;&#x000a0;0.01*</td><td align="left">2.99&#x000a0;&#x000b1;&#x000a0;0.15</td><td align="left">0.66&#x000a0;&#x000b1;&#x000a0;0.09</td></tr><tr><td align="left">AP</td><td align="left" colspan="5">4 donor hearts; 8 myocytes</td></tr><tr><td align="left">Before</td><td align="left">34.1&#x000a0;&#x000b1;&#x000a0;4.5</td><td align="left">1.5&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">5.48&#x000a0;&#x000b1;&#x000a0;0.02</td><td align="left">4.04&#x000a0;&#x000b1;&#x000a0;0.19</td><td align="left">0.62&#x000a0;&#x000b1;&#x000a0;0.09</td></tr><tr><td align="left">After</td><td align="left">34.3&#x000a0;&#x000b1;&#x000a0;4.9</td><td align="left">2.0&#x000a0;&#x000b1;&#x000a0;0.4*</td><td align="left">5.57&#x000a0;&#x000b1;&#x000a0;0.02*</td><td align="left">3.33&#x000a0;&#x000b1;&#x000a0;0.18*</td><td align="left">0.67&#x000a0;&#x000b1;&#x000a0;0.07</td></tr><tr><td align="left">AP&#x000a0;+&#x000a0;PKC&#x003b1;</td><td align="left" colspan="5">4 donor hearts; 7 myocytes</td></tr><tr><td align="left">Before</td><td align="left">31.6&#x000a0;&#x000b1;&#x000a0;4.4</td><td align="left">2.2&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="left">5.59&#x000a0;&#x000b1;&#x000a0;0.02</td><td align="left">3.25&#x000a0;&#x000b1;&#x000a0;0.18</td><td align="left">0.57&#x000a0;&#x000b1;&#x000a0;0.04</td></tr><tr><td align="left">After</td><td align="left">31.3&#x000a0;&#x000b1;&#x000a0;4.8</td><td align="left">2.0&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="left">5.51&#x000a0;&#x000b1;&#x000a0;0.02*</td><td align="left">3.30&#x000a0;&#x000b1;&#x000a0;0.15</td><td align="left">0.76&#x000a0;&#x000b1;&#x000a0;0.07*</td></tr></tbody></table><table-wrap-foot><p>F<sub>max</sub>, maximal force at maximal calcium concentration in kN/m<sup>2</sup>; <italic>F</italic><sub>pass</sub>, passive force measured in free calcium solution in kN/m<sup>2</sup>; nH, steepness of the force-pCa curves</p><p>*&#x000a0;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, before versus after incubation in paired <italic>t</italic> test</p><p><sup>#</sup>&#x000a0;Time control incubations</p></table-wrap-foot></table-wrap></p><p>Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c shows a phosphoprotein (ProQ) stained 1D gel of failing tissue samples treated with PKC&#x003b1; and PKC&#x003b5;, at concentrations of 10 and 50&#x000a0;&#x003bc;g/mL. The phosphorylated active forms of PKC&#x003b1; and PKC&#x003b5; became apparent in the incubations with 50&#x000a0;&#x003bc;g/mL kinase. Gels were subsequently stained with SYPRO Ruby to correct for differences in protein loading. The phosphorylation levels with 50&#x000a0;&#x003bc;g/mL kinase were similar to the incubations with 10&#x000a0;&#x003bc;g/mL kinase, indicating that the standard concentrations of 10&#x000a0;&#x003bc;g/mL kinase yielded the maximum obtainable phosphorylation level. To further investigate if PKC&#x003b1; and PKC&#x003b5; are able to phosphorylate cTn, recombinant human troponin complex [<xref ref-type="bibr" rid="CR43">43</xref>] was incubated with both isoforms. The results on the recombinant, non-phosphorylated troponin complex clearly indicate that PKC&#x003b1; and PKC&#x003b5; both phosphorylate cTnT and cTnI and that the efficacy of PKC&#x003b5; was less than that of PKC&#x003b1; (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d).</p><p>Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>e shows that PKC&#x003b1; (<italic>n</italic>&#x000a0;=&#x000a0;5) and PKC&#x003b5; (<italic>n</italic>&#x000a0;=&#x000a0;2) caused pronounced (2- to 3-fold) increases in cTnI and cMyBP-C phosphorylation in failing myocardium (relative to the control incubation without kinase which was set to 1). The relative increase in cMyBP-C phosphorylation by PKC&#x003b5; (3.4&#x000a0;&#x000b1;&#x000a0;0.5) was somewhat higher to that observed with PKC&#x003b1; (2.1&#x000a0;&#x000b1;&#x000a0;0.4), while phosphorylation of cTnI with PKC&#x003b5; (1.6&#x000a0;&#x000b1;&#x000a0;0.1) was lower compared with PKC&#x003b1; (2.9&#x000a0;&#x000b1;&#x000a0;0.6). A minor increase in desmin phosphorylation was observed with both isoforms, while only PKC&#x003b1; slightly increased cTnT phosphorylation. No effects were observed on phosphorylation of myosin light chain 2 (MLC-2). As PKC&#x003b1; lowered passive force, the effect of PKC&#x003b1; incubation on the phosphorylation of cardiac titin was analyzed in failing (<italic>n</italic>&#x000a0;=&#x000a0;5) and donor (<italic>n</italic>&#x000a0;=&#x000a0;6) tissue. Incubation with PKC&#x003b1; did not result in a significant change in titin phosphorylation in both donor and failing tissue (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a, b).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Effect of PKC&#x003b1; incubation on the phosphorylation of titin in failing (<italic>n</italic>&#x000a0;=&#x000a0;5) and donor (<italic>n</italic>&#x000a0;=&#x000a0;6) tissue. Sypro and ProQ stained agarose strengthened 5% sodium dodecyl sulfate-polyacrylamide gels of donor and failing tissue samples incubated with and without PKC&#x003b1;. Phosphorylation of myofilament proteins was expressed relative to the Sypro Ruby-stained titin bands to correct for differences in protein loading. Incubation with PKC&#x003b1; did not result in a significant increase of titin phosphorylation both in donor and failing tissue (<bold>a</bold>, <bold>b</bold>). Kinase versus control incubation in paired <italic>t</italic> test</p></caption><graphic xlink:href="395_2009_53_Fig2_HTML" id="MO2"/></fig></p><p>To address the origin of the shift in Ca<sup>2+</sup> sensitivity in failing hearts, cells were treated with PKA after incubation with PKC&#x003b1; and &#x003b5;. This resulted in a further reduction in Ca<sup>2+</sup> sensitivity (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a, b), without any significant effect on <italic>F</italic><sub>max</sub> and <italic>F</italic><sub>pas</sub> (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>a). Reversal of the PKA and PKC&#x003b1;/&#x003b5; sequences yielded similar reductions in Ca<sup>2+</sup> sensitivity for PKA and PKC&#x003b1; and &#x003b5;, indicating that the effects of PKC&#x003b1; and &#x003b5; on Ca<sup>2+</sup> sensitivity were independent of that of PKA (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c, d; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>a).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>PKC&#x003b1; and &#x003b5; do not cross-phosphorylate the PKA sites (Ser23/24). After the first force-pCa series (control, before incubation) myocytes from failing hearts were incubated with PKC&#x003b1; or PKC&#x003b5; and a second force-pCa series was measured. Thereafter the myocytes were incubated with PKA, which saturates the PKA sites on cTnI and the third force-pCa series was measured (<bold>a</bold>, <bold>b</bold>). PKC&#x003b1;-PKA, <italic>n</italic>&#x000a0;=&#x000a0;9; PKC&#x003b5;-PKA, <italic>n</italic>&#x000a0;=&#x000a0;7. PKC&#x003b1; and PKC&#x003b5; caused a reduction in Ca<sup>2+</sup> sensitivity and subsequent incubation with PKA results in a further reduction of Ca<sup>2+</sup> sensitivity. Reversal of the order of application of the PKC isoforms and PKA (<bold>c</bold>, <bold>d</bold>) resulted in similar reductions in pCa<sub>50</sub>. PKA&#x02013;PKC&#x003b1;, <italic>n</italic>&#x000a0;=&#x000a0;8; PKA&#x02013;PKC&#x003b5;, <italic>n</italic>&#x000a0;=&#x000a0;6. <sup>#</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, in repeated measures ANOVA. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, before versus after kinase treatment in Bonferroni post hoc test</p></caption><graphic xlink:href="395_2009_53_Fig3_HTML" id="MO3"/></fig></p><p>On average, <italic>K</italic><sub>tr</sub>-max [tension redevelopment rate (s<sup>&#x02212;1</sup>) at maximal Ca<sup>2+</sup> concentration] was significantly increased after PKC&#x003b1;, PKC&#x003b5; and PKA incubation in failing cardiomyocytes (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>a). However, it must be noted that the change in <italic>K</italic><sub>tr</sub>-max in failing cells upon kinase treatments did not significantly differ from the increase observed in the (time) control incubations (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>a). These results suggest that the kinases and phosphatase used have little, if any, effect on the kinetics of force redevelopment at saturating calcium concentration.</p></sec><sec id="Sec11"><title>PKC&#x003b1; decreases Ca<sup>2+</sup> sensitivity via cTnT phosphorylation</title><p>As observed in a previous study [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], analysis of baseline endogenous myofilament protein phosphorylation revealed significantly higher cMyBP-C and cTnI phosphorylation in donor samples in comparison to failing samples, while no significant differences in phosphorylation were observed for desmin, cTnT and MLC-2 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a). <italic>F</italic><sub>max</sub> and <italic>F</italic><sub>pas</sub> did not significantly differ between failing (<italic>n</italic>&#x000a0;=&#x000a0;56; <italic>F</italic><sub>max</sub> 31.7&#x000a0;&#x000b1;&#x000a0;1.5&#x000a0;kN/m<sup>2</sup> and <italic>F</italic><sub>pas</sub> 1.6&#x000a0;&#x000b1;&#x000a0;0.1&#x000a0;kN/m<sup>2</sup>) and donor (<italic>n</italic>&#x000a0;=&#x000a0;20; <italic>F</italic><sub>max</sub> 33.8&#x000a0;&#x000b1;&#x000a0;3.0&#x000a0;kN/m<sup>2</sup> and <italic>F</italic><sub>pas</sub> 1.8&#x000a0;&#x000b1;&#x000a0;0.2&#x000a0;kN/m<sup>2</sup>) cardiomyocytes, while Ca<sup>2+</sup> sensitivity of the myofilaments was significantly higher in failing (5.66&#x000a0;&#x000b1;&#x000a0;0.01; <italic>n</italic>&#x000a0;=&#x000a0;54) compared to donor (5.50&#x000a0;&#x000b1;&#x000a0;0.01; <italic>n</italic>&#x000a0;=&#x000a0;20) myocardium. In addition the steepness of the pCa-force relationship (nH) was slightly lower in failing (3.48&#x000a0;&#x000b1;&#x000a0;0.09; <italic>n</italic>&#x000a0;=&#x000a0;54) compared to donor (3.85&#x000a0;&#x000b1;&#x000a0;0.19; <italic>n</italic>&#x000a0;=&#x000a0;20) cells (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05). <italic>K</italic><sub>tr</sub>-max was slightly, though not significantly, higher in failing (0.84&#x000a0;&#x000b1;&#x000a0;0.02 s<sup>&#x02212;1</sup>; <italic>n</italic>&#x000a0;=&#x000a0;56) than in donor (0.77&#x000a0;&#x000b1;&#x000a0;0.03 s<sup>&#x02212;1</sup>; <italic>n</italic>&#x000a0;=&#x000a0;20) cells. Previous analysis using two-dimensional gel electrophoresis revealed that endogenous cTnT phosphorylation is high (~63%), both in donor and failing myocardium [<xref ref-type="bibr" rid="CR36">36</xref>]. To uncover functional effects of PKC&#x003b1;-mediated cTnT phosphorylation in human tissue, PKC&#x003b1; incubations were repeated after pretreatment of failing and donor cardiomyocytes with AP. AP significantly reduced cTnT phosphorylation to 15% of its original level in donor and to 17% in failing myocardium without dephosphorylation of cTnI (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a, b). AP treatment also significantly reduced phosphorylation of cMyBP-C (~30%) in donor myocardium, and of desmin (~30%) in failing tissue. Subsequent phosphorylation by PKC&#x003b1; of samples dephosphorylated by AP resulted in significant increases in cTnT phosphorylation in failing (170%) and in donor tissue (95%). In addition, PKC&#x003b1; significantly increased phosphorylation of cMyBP-C (~23%), desmin (~113%), cTnI (~160%) and MLC-2 (~80%) in failing tissue, while in AP pre-treated donor tissue, cTnT was the only protein phosphorylated by PKC&#x003b1; (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>c).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Basal phosphorylation of donor versus failing tissue and the effect of PKC&#x003b1; phosphorylation on donor tissue. <bold>a</bold> Endogenous phosphorylation of myosin binding protein C (cMyBP-C) and troponin I (cTnI) was significantly lower in failing (<italic>n</italic>&#x000a0;=&#x000a0;10) compared to non-failing donor (<italic>n</italic>&#x000a0;=&#x000a0;4) samples. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, donor versus failing in unpaired <italic>t</italic> test. <bold>b</bold> PKC&#x003b1; treatment did not alter force characteristics of non-failing donor cardiomyocytes. <bold>c</bold> Average data using 10&#x000a0;&#x003bc;g/mL of PKC&#x003b1; in samples from donor (<italic>n</italic>&#x000a0;=&#x000a0;4) hearts. In donor tissue the only significant effect was a small (9&#x000a0;&#x000b1;&#x000a0;3%) increase in cMyBP-C phosphorylation. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, kinase versus control incubation in paired <italic>t</italic> test</p></caption><graphic xlink:href="395_2009_53_Fig4_HTML" id="MO4"/></fig><fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Effect of alkaline phosphatase (AP) treatment and the subsequent effect of PKC&#x003b1; on myofilament protein phosphorylation in donor and failing myocardium. <bold>a</bold> 1D gradient gel stained with ProQ diamond from donor and failing myocardium incubated without kinase or phosphatase (C), with PKC&#x003b1;, with AP and with AP followed by PKC&#x003b1; (AP&#x000a0;+&#x000a0;PKC&#x003b1;). <italic>MM</italic> molecular weight marker, <italic>PM</italic> PeppermintStick Phosphoprotein marker (Molecular Probes). <bold>b</bold> Changes in phosphorylation of cTnT by AP relative to time control without phosphatase in failing (<italic>n</italic>&#x000a0;=&#x000a0;5) and donor (<italic>n</italic>&#x000a0;=&#x000a0;6) myocardium. <bold>c</bold> Changes in phosphorylation by PKC&#x003b1; upon AP pretreatment relative to the values obtained after AP pretreatment (<italic>n</italic>&#x000a0;=&#x000a0;4 in both groups). *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, PKC&#x003b1; relative to control in paired <italic>t</italic> test</p></caption><graphic xlink:href="395_2009_53_Fig5_HTML" id="MO5"/></fig></p><p>After the massive dephosphorylation of cTnT, the effects of PKC&#x003b1; on cardiomyocyte function were studied. AP treatment resulted in an increase in Ca<sup>2+</sup> sensitivity, which was similar in failing and donor tissue (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a, b; &#x00394;pCa<sub>50</sub>&#x000a0;=&#x000a0;0.09). Subsequent treatment with PKC&#x003b1; resulted in a decline in Ca<sup>2+</sup> sensitivity to a level (pCa<sub>50</sub> after AP-PKC&#x003b1;: 5.60&#x000a0;&#x000b1;&#x000a0;0.01 and 5.51&#x000a0;&#x000b1;&#x000a0;0.02 in failing and donor, respectively) similar to that observed after PKC&#x003b1; treatment, without AP pretreatment (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>b). The steepness of the force-pCa relation decreased upon AP in failing and donor cells and remained low after PKC&#x003b1; (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>b). A similar decline in steepness of the Ca<sup>2+</sup> sensitivity curve was observed in the time control experiments in the absence of kinase or phosphatase. AP treatment resulted in a small but significant increase in <italic>F</italic><sub>max</sub> in failing cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c). In donor cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>d) no effect on <italic>F</italic><sub>max</sub> was observed. PKC&#x003b1; applied after AP treatment did not affect <italic>F</italic><sub>max</sub> in both groups. AP also caused a significant increase in <italic>F</italic><sub>pas</sub> in both failing and donor cells (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>e, f), but subsequent PKC&#x003b1; treatment failed to restore the original levels.<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>The effects of PKC&#x003b1; after dephosphorylation of cTnT by alkaline phosphatase (AP) in failing (<italic>n</italic>&#x000a0;=&#x000a0;5) and donor (<italic>n</italic>&#x000a0;=&#x000a0;4) tissue. Ca<sup>2+</sup> sensitivity of force was increased after AP treatment and was subsequently reduced after PKC&#x003b1; treatment to the levels observed without AP pretreatment (<bold>a</bold>, <bold>b</bold>). AP treatment resulted in a minor but significant increase in maximum force (<italic>F</italic><sub>max</sub>) in failing tissue while in donor tissue no change was observed (<bold>c</bold>, <bold>d</bold>). Subsequent treatment with PKC&#x003b1; had no effect on <italic>F</italic><sub>max</sub>. Passive force (<italic>F</italic><sub>pas</sub>) (<bold>e</bold>, <bold>f</bold>) was increased after AP in failing and donor tissue and remained elevated after PKC&#x003b1; treatment. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, before versus after phosphatase/kinase treatment in Bonferroni post hoc test</p></caption><graphic xlink:href="395_2009_53_Fig6_HTML" id="MO6"/></fig></p></sec></sec><sec id="Sec12"><title>Discussion</title><p>This study shows that PKC-mediated phosphorylation of cMyBP-C and cTnI as well as of cTnT cause a reduction of Ca<sup>2+</sup> sensitivity of force development in human myocardium. No effects on maximal force generating capacity of the myofilaments were observed, neither upon direct PKC treatment nor following phosphatase pretreatment. On the basis of these data we propose that increased PKC activity in failing myocardium may depress systolic function of the heart as for the same intracellular Ca<sup>2+</sup> concentration, the myofilament force generation and thereby developed pressure will be reduced. On the other hand, the reduced myofilament Ca<sup>2+</sup> sensitivity may help myocardial relaxation as Ca<sup>2+</sup> concentrations are increased in failing hearts [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><sec id="Sec13"><title>PKC&#x003b1; and PKC&#x003b5; phosphorylation of cTnI and cMyBP-C decrease Ca<sup>2+</sup> sensitivity in failing myocardium</title><p>Direct incubation of the cardiomyocytes from failing hearts with saturating amounts of active PKC&#x003b1; and PKC&#x003b5; resulted in a decrease in Ca<sup>2+</sup> sensitivity (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). PKC&#x003b1; and PKC&#x003b5; incubations of failing tissue resulted in increased phosphorylation of cMyBP-C and cTnI. PKC&#x003b1; incubation resulted in higher phosphorylation of cTnI and PKC&#x003b5; in higher phosphorylation levels of cMyBP-C, indicating isozyme specific substrate affinity. Although phosphorylation effects were diverse, the functional consequences of both PKC isoforms were quite similar.</p><p>It has previously been determined that cMyBP-C has PKC-phosphorylatable residues [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. However, so far no data has been published (to our knowledge) that directly link cMyBP-C phosphorylation with alterations in Ca<sup>2+</sup> sensitivity. Our data suggest involvement of PKC-mediated cMyBP-C phosphorylation in the reduced Ca<sup>2+</sup> sensitivity observed in failing tissue.</p><p>Kobayashi et al. [<xref ref-type="bibr" rid="CR20">20</xref>] indicated that PKC&#x003b5; was able to phosphorylate PKA sites on mouse cTnI. Our previous study also showed that the active catalytic domain of PKC caused cross-phosphorylation of the PKA sites (Ser23/24) [<xref ref-type="bibr" rid="CR35">35</xref>]. We addressed this issue for PKC&#x003b1;- and PKC&#x003b5;-mediated phosphorylation by performing experiments where incubations of PKC&#x003b1; or PKC&#x003b5; were followed by PKA as well as by incubations in the reverse order. The results showed that the shifts in Ca<sup>2+</sup> sensitivity in failing myocardium did not depend on the sequence of application of PKA and PKC&#x003b1;/&#x003b5;. This indicates that the effects of the PKC isoforms and PKA were independent and that the PKC&#x003b1;/&#x003b5;-mediated effects were not caused by cross-phosphorylation of the PKA sites under our conditions. Kobayashi et al. [<xref ref-type="bibr" rid="CR20">20</xref>] used the recombinant mouse cTnI and an excess of PKC&#x003b5;, therefore it is possible that the cross-phosphorylation they observed does not occur under more physiological conditions or that it is more pronounced in mice than in human cTn.</p></sec><sec id="Sec14"><title>PKC&#x003b1; decreases Ca<sup>2+</sup> sensitivity via cTnT phosphorylation</title><p>Direct incubation of donor cells with PKC&#x003b1; did not alter Ca<sup>2+</sup> sensitivity (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b), which is in line with minor effects of PKC&#x003b1; on protein phosphorylation of cMyBP-C, desmin, cTnI, cTnT and MLC2 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c). The absence of functional effects of PKC&#x003b1; is most likely explained by the relatively high baseline phosphorylation status of cMyBP-C, cTnI and cTnT in donor myocardium. Because endogenous cMyBP-C and cTnI phosphorylation levels in donor tissue were high (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a) and no major effects of PKC&#x003b1; on Ca<sup>2+</sup> sensitivity and protein phosphorylation were observed (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b, c), the donor tissue was used as a tool to reveal functional effects of PKC&#x003b1;-mediated phosphorylation of cTnT.</p><p>AP treatment resulted in a massive decrease in cTnT phosphorylation in failing and donor myocardium. Subsequent treatment with PKC&#x003b1; solely increased phosphorylation of cTnT in donor myocardium, which made it possible to identify the role of cTnT upon phosphorylation by PKC&#x003b1;. Treatment with PKC&#x003b1; following AP treatment showed a significant reduction in Ca<sup>2+</sup> sensitivity in both failing and donor tissue. These results indicate that AP is able to dephosphorylate sites on cTnT, which are subsequently targeted by PKC&#x003b1; and when phosphorylated reduce Ca<sup>2+</sup> sensitivity.</p><p>Overall, our results are in agreement with previous animal studies [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR40">40</xref>] indicating that functionally relevant targets of PKC&#x003b1;- and PKC&#x003b5;-mediated Ca<sup>2+</sup> desensitization of the myofilaments are located on cardiac troponin. Both cTnI and cTnT contain a number of different PKC-phosphorylatable sites. On the basis of biochemical in vitro studies Ser-42 and Ser-44 and Thr-143 on cTnI [<xref ref-type="bibr" rid="CR30">30</xref>] and Thr-194, Ser-198, Thr-203 and Thr-284 on cTnT [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] are considered the main sites (phosphorylated sites based on human sequence). It has been proposed that the relative balance of phosphorylation of the three PKC sites on cTnI is important for the regulation of its function [<xref ref-type="bibr" rid="CR32">32</xref>]. Pseudophosphorylation of Ser-42/Ser-44 significantly reduced the myofilament response to calcium and phosphorylation of Thr-143 induced an increase in sensitivity to calcium [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Among the four phosphorylation sites on cTnT, Thr-203 appeared to be the most important for modulation of cTn function in that it inhibited force as well as its Ca<sup>2+</sup> sensitivity [<xref ref-type="bibr" rid="CR33">33</xref>].</p></sec><sec id="Sec15"><title>PKC&#x003b1; reduces passive force, but not maximal force</title><p>Rodent studies indicate that PKC-mediated phosphorylation results in a reduction of the maximum force generating capacity of the cardiomyocytes [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. A study using an in vitro motility assay suggested that this might also be the case in human tissue [<xref ref-type="bibr" rid="CR2">2</xref>]. However, the present results did not show depression of force upon PKC treatment and indicate that caution should be exerted when extrapolating data obtained in rodent studies to force development in human cardiomyocytes. Cardiac cTnI and cTnT phosphorylation by PKC may occur at different sites in different species and may explain the absence of an effect of PKC&#x003b1; on <italic>F</italic><sub>max</sub> in human cardiomyocytes. Only recently, using mass spectrometry Zabrouskov et al. [<xref ref-type="bibr" rid="CR42">42</xref>] revealed a novel phosphorylation site (Ser-76 or Thr-77) in human cTnI, while no phosphorylation was observed at the sites mentioned above. A study in mice revealed that the PKC&#x003b1;-induced reduction in <italic>F</italic><sub>max</sub> critically depended on cTnT phosphorylation at Thr-203 [<xref ref-type="bibr" rid="CR33">33</xref>]. Future studies should be performed to reveal which sites are phosphorylated by PKC in human myocardium. Recently Moln&#x000e1;r et al. [<xref ref-type="bibr" rid="CR25">25</xref>] showed that PKC&#x003b1; contributes to the maintenance of contractile force in human cardiomyocytes, which is in line with our results that PKC&#x003b1; treatment does not negatively affect maximal force. AP treatment resulted in a small (~5%) but significant increase in <italic>F</italic><sub>max</sub>. However, subsequent treatment with PKC&#x003b1; did not result in a reduction of force development. This suggests that AP is able to dephosphorylate at least to some extent one of the contractile proteins determining <italic>F</italic><sub>max</sub>. However, in human tissue the impact is rather small and the link with PKC&#x003b1; is not evident.</p><p>PKC&#x003b1; treatment resulted in a small reduction of <italic>F</italic><sub>pas</sub> both in donor and in failing cardiomyocytes, whereas PKC&#x003b5; had no significant effect but did show a similar trend (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). AP treatment caused a significant increase in <italic>F</italic><sub>pas</sub> in both failing and donor cells but subsequent PKC&#x003b1; treatment did not restore the original levels. These results suggest that the effects of PKC&#x003b1;-mediated phosphorylation and AP-induced dephosphorylation on stiffness are independent, and indicate that at least two distinct phosphorylation sites, possibly on titin [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR41">41</xref>], are involved in the modulation of passive stiffness of the cardiomyocytes. To address this issue, the effect of PKC&#x003b1; in titin phosphorylation after incubation with PKC&#x003b1; was investigated both in donor and failing tissue (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). However, no significant effect was observed. This could imply that phosphorylation of titin is not solely responsible for the decrease in passive force observed after PKC&#x003b1;. However, since titin may contain numerous phosphorylation sites with one or few PKC&#x003b1; dependent sites, it might be that our method is not sensitive enough to resolve the minor relative changes in titin phosphorylation as appeared to be the case for protein kinase G by Kr&#x000fc;ger et al. [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>As high <italic>F</italic><sub>pas</sub> has been associated with high left ventricular end-diastolic pressure in patients with diastolic dysfunction [<xref ref-type="bibr" rid="CR4">4</xref>], the reduction in passive stiffness by PKC&#x003b1;-mediated phosphorylation might improve diastolic filling of the heart.</p></sec></sec><sec id="Sec16"><title>Limitations and conclusions</title><p>In this study the effects of the kinases and phosphatases on the phosphorylation levels are represented relative to basal phosphorylation levels for each protein. Although the changes in protein phosphorylation levels were relatively small, the functional changes were significant and may be physiologically relevant.</p><p>Since the transition to end-stage heart failure is accompanied by an increase in PKC&#x003b1; activity [<xref ref-type="bibr" rid="CR6">6</xref>] it is surprising that the effects of PKC&#x003b1; are observed only in end-stage failing hearts and become visible in donor hearts only after dephosphorylation by alkaline phosphatase. It should be noted, however, that the endogenous phosphorylation levels in the explanted myocardium studied not necessarily reflect the in vivo situation. The lower levels of cMyBP-C and cTnI phosphorylation observed in end-stage failing compared to donor myocardium may reflect desensitisation of the &#x003b2;-adrenergic pathway. Moreover, it has been suggested that high catecholamine levels at the time of tissue procurement underlies the relative high levels of cMyBP-C and cTnI phosphorylation levels in donor myocardium [<xref ref-type="bibr" rid="CR23">23</xref>]. Future studies in biopsy samples taken under well-controlled hemodynamic conditions with parallel measurements of blood catecholamines should be performed to address this issue. Nevertheless, the data presented in this study clearly indicate that changes in expression and activation of PKC&#x003b1; and PKC&#x003b5; in response to pathophysiological stressors or increased hemodynamic demands during exercise translate into alterations in contractile function in human myocardium.</p></sec></body><back><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayer</surname><given-names>AL</given-names></name><name><surname>Heidkamp</surname><given-names>MC</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Porter</surname><given-names>M</given-names></name><name><surname>Engman</surname><given-names>S</given-names></name><name><surname>Samarel</surname><given-names>AM</given-names></name></person-group><article-title>Alterations in protein kinase C isoenzyme expression and autophosphorylation during the progression of pressure overload-induced left ventricular hypertrophy</article-title><source>Mol Cell Biochem</source><year>2003</year><volume>242</volume><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1023/A:1021106232511</pub-id><pub-id pub-id-type="pmid">12619877</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belin</surname><given-names>RJ</given-names></name><name><surname>Sumandea</surname><given-names>MP</given-names></name><name><surname>Allen</surname><given-names>EJ</given-names></name><name><surname>Schoenfelt</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Solaro</surname><given-names>JR</given-names></name><name><surname>Tombe</surname><given-names>PP</given-names></name></person-group><article-title>Augmented Protein Kinase C-&#x003b1;-induced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure</article-title><source>Circ Res</source><year>2007</year><volume>101</volume><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.148288</pub-id><pub-id pub-id-type="pmid">17556659</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f8;kenes</surname><given-names>J</given-names></name><name><surname>Aronsen</surname><given-names>JM</given-names></name><name><surname>Birkeland</surname><given-names>JA</given-names></name><name><surname>Henriksen</surname><given-names>UL</given-names></name><name><surname>Louch</surname><given-names>WE</given-names></name><name><surname>Sjaastad</surname><given-names>I</given-names></name><name><surname>Sejersted</surname><given-names>OM</given-names></name></person-group><article-title>Slow contractions characterize failing rat hearts</article-title><source>Basic Res Cardiol</source><year>2008</year><volume>103</volume><fpage>328</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1007/s00395-008-0719-y</pub-id><pub-id pub-id-type="pmid">18347833</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borb&#x000e9;ly</surname><given-names>A</given-names></name><name><surname>Velden</surname><given-names>J</given-names></name><name><surname>Bronzwaer</surname><given-names>JGF</given-names></name><name><surname>Papp</surname><given-names>Z</given-names></name><name><surname>&#x000c9;des</surname><given-names>I</given-names></name><name><surname>Stienen</surname><given-names>GJM</given-names></name><name><surname>Paulus</surname><given-names>WJ</given-names></name></person-group><article-title>Cardiomyocyte stiffness in diastolic heart failure</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>774</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000155257.33485.6D</pub-id><pub-id pub-id-type="pmid">15699264</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borb&#x000e9;ly</surname><given-names>A</given-names></name><name><surname>Falcao-Pires</surname><given-names>I</given-names></name><name><surname>Heerebeek</surname><given-names>L</given-names></name><name><surname>Hamdani</surname><given-names>N</given-names></name><name><surname>&#x000c9;des</surname><given-names>I</given-names></name><name><surname>Gavina</surname><given-names>C</given-names></name><name><surname>Leite-Moreira</surname><given-names>AF</given-names></name><name><surname>Bronzwaer</surname><given-names>JGF</given-names></name><name><surname>Papp</surname><given-names>Z</given-names></name><name><surname>Velden</surname><given-names>J</given-names></name><name><surname>Stienen</surname><given-names>GJM</given-names></name><name><surname>Paulus</surname><given-names>WJ</given-names></name></person-group><article-title>Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium</article-title><source>Circ Res</source><year>2009</year><volume>104</volume><fpage>780</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.193326</pub-id><pub-id pub-id-type="pmid">19179657</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowling</surname><given-names>N</given-names></name><name><surname>Walsh</surname><given-names>RA</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Estridge</surname><given-names>T</given-names></name><name><surname>Sandusky</surname><given-names>GE</given-names></name><name><surname>Fouts</surname><given-names>RL</given-names></name><name><surname>Mintze</surname><given-names>K</given-names></name><name><surname>Pickard</surname><given-names>T</given-names></name><name><surname>Roden</surname><given-names>R</given-names></name><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Sabbah</surname><given-names>HN</given-names></name><name><surname>Mizrahi</surname><given-names>JL</given-names></name><name><surname>Gromo</surname><given-names>G</given-names></name><name><surname>King</surname><given-names>GL</given-names></name><name><surname>Vlahos</surname><given-names>CJ</given-names></name></person-group><article-title>Increased protein kinase C activity and expression of Ca<sup>2+</sup>-sensitive isoforms in the failing human heart</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>384</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">9918525</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braz</surname><given-names>JC</given-names></name><name><surname>Gregory</surname><given-names>K</given-names></name><name><surname>Pathak</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Sahin</surname><given-names>B</given-names></name><name><surname>Klevitsky</surname><given-names>R</given-names></name><name><surname>Kimball</surname><given-names>TF</given-names></name><name><surname>Lorenz</surname><given-names>JN</given-names></name><name><surname>Nairn</surname><given-names>AC</given-names></name><name><surname>Liggett</surname><given-names>SB</given-names></name><name><surname>Bodi</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>A</given-names></name><name><surname>Lakatta</surname><given-names>EG</given-names></name><name><surname>DePaoli-Roach</surname><given-names>AA</given-names></name><name><surname>Robbins</surname><given-names>J</given-names></name><name><surname>Hewett</surname><given-names>TE</given-names></name><name><surname>Bibb</surname><given-names>JA</given-names></name><name><surname>Westfall</surname><given-names>MV</given-names></name><name><surname>Kranias</surname><given-names>EG</given-names></name><name><surname>Molkentin</surname><given-names>JD</given-names></name></person-group><article-title>PKC-&#x003b1; regulates cardiac contractility and propensity toward heart failure</article-title><source>Nature</source><year>2004</year><volume>10</volume><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/nm1000</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkart</surname><given-names>EM</given-names></name><name><surname>Sumandea</surname><given-names>MP</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Nili</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>AF</given-names></name><name><surname>Homsher</surname><given-names>E</given-names></name><name><surname>Solaro</surname><given-names>RJ</given-names></name></person-group><article-title>Phosphorylation or glutamic acid substitution at protein kinase C sites on cardiac troponin I differentially depress myofilament tension and shortening velocity</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>11265</fpage><lpage>11272</lpage><pub-id pub-id-type="doi">10.1074/jbc.M210712200</pub-id><pub-id pub-id-type="pmid">12551921</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Monte</surname><given-names>F</given-names></name><name><surname>Johnson</surname><given-names>CM</given-names></name><name><surname>Stepanek</surname><given-names>AC</given-names></name><name><surname>Doye</surname><given-names>AA</given-names></name><name><surname>Gwathmey</surname><given-names>JK</given-names></name></person-group><article-title>Defects in calcium control</article-title><source>J Card Fail</source><year>2002</year><volume>8</volume><fpage>421</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1054/jcaf.2002.129285</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorn</surname><given-names>GW</given-names><suffix>II</suffix></name><name><surname>Souroujan</surname><given-names>MC</given-names></name><name><surname>Liron</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Gray</surname><given-names>MO</given-names></name><name><surname>Zhou</surname><given-names>HZ</given-names></name><name><surname>Csukai</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Lorenz</surname><given-names>JN</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name></person-group><article-title>Sustained in vivo cardiac protection by a rationally designed peptide that causes &#x003b5; protein kinase C translocation</article-title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>12798</fpage><lpage>12803</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.22.12798</pub-id><pub-id pub-id-type="pmid">10536002</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldsprink</surname><given-names>PH</given-names></name><name><surname>Montgomery</surname><given-names>DE</given-names></name><name><surname>Walker</surname><given-names>LA</given-names></name><name><surname>Urboniene</surname><given-names>D</given-names></name><name><surname>McKinney</surname><given-names>RD</given-names></name><name><surname>Geenen</surname><given-names>DL</given-names></name><name><surname>Solaro</surname><given-names>RJ</given-names></name><name><surname>Buttrick</surname><given-names>PM</given-names></name></person-group><article-title>Protein kinase C epsilon overexpression alters myofilament properties and composition during the progression of heart failure</article-title><source>Circ Res</source><year>2004</year><volume>95</volume><fpage>424</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000138299.85648.92</pub-id><pub-id pub-id-type="pmid">15242976</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>HS</given-names></name><name><surname>Marreez</surname><given-names>Y</given-names></name><name><surname>Odley</surname><given-names>A</given-names></name><name><surname>Sterbling</surname><given-names>A</given-names></name><name><surname>Yussman</surname><given-names>MG</given-names></name><name><surname>Hilty</surname><given-names>KC</given-names></name><name><surname>Bodi</surname><given-names>I</given-names></name><name><surname>Liggett</surname><given-names>SB</given-names></name><name><surname>Schwartz</surname><given-names>A</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names><suffix>2nd</suffix></name></person-group><article-title>Protein kinase C alpha negatively regulates systolic and diastolic function in pathological hypertrophy</article-title><source>Circ Res</source><year>2003</year><volume>93</volume><fpage>1111</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000105087.79373.17</pub-id><pub-id pub-id-type="pmid">14605019</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hambleton</surname><given-names>M</given-names></name><name><surname>Hahn</surname><given-names>H</given-names></name><name><surname>Pleger</surname><given-names>ST</given-names></name><name><surname>Kuhn</surname><given-names>MC</given-names></name><name><surname>Klevitsky</surname><given-names>R</given-names></name><name><surname>Carr</surname><given-names>AN</given-names></name><name><surname>Kimball</surname><given-names>TF</given-names></name><name><surname>Hewett</surname><given-names>TE</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names><suffix>2nd</suffix></name><name><surname>Koch</surname><given-names>WJ</given-names></name><name><surname>Molkentin</surname><given-names>JD</given-names></name></person-group><article-title>Pharmacological- and gene therapy-based inhibition of protein kinase C alpha/beta enhances cardiac contractility and attenuates heart failure</article-title><source>Circulation</source><year>2006</year><volume>114</volume><fpage>574</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.592550</pub-id><pub-id pub-id-type="pmid">16880328</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamdani</surname><given-names>N</given-names></name><name><surname>Kooij</surname><given-names>V</given-names></name><name><surname>Dijk</surname><given-names>S</given-names></name><name><surname>Merkus</surname><given-names>D</given-names></name><name><surname>Paulus</surname><given-names>WJ</given-names></name><name><surname>dos Remedios</surname><given-names>C</given-names></name><name><surname>Duncker</surname><given-names>DJ</given-names></name><name><surname>Stienen</surname><given-names>GJM</given-names></name><name><surname>Velden</surname><given-names>J</given-names></name></person-group><article-title>Sarcomeric dysfunction in heart failure</article-title><source>Cardiovasc Res</source><year>2008</year><volume>77</volume><fpage>649</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvm079</pub-id><pub-id pub-id-type="pmid">18055579</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>XP</given-names></name><name><surname>Pi</surname><given-names>Y</given-names></name><name><surname>Lokuta</surname><given-names>AJ</given-names></name><name><surname>Greaser</surname><given-names>ML</given-names></name><name><surname>Walker</surname><given-names>JW</given-names></name></person-group><article-title>Arachidonic acid stimulated protein kinase C-&#x003b5; resdistribution in heart cells</article-title><source>J Cell Science</source><year>1997</year><volume>110</volume><fpage>1625</fpage><lpage>1634</lpage><pub-id pub-id-type="pmid">9247196</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>XP</given-names></name><name><surname>Walker</surname><given-names>JW</given-names></name></person-group><article-title>Myofilament anchoring of protein kinase C-epsilon in cardiac myocytes</article-title><source>J Cell Science</source><year>2003</year><volume>117</volume><fpage>1971</fpage><lpage>1978</lpage><pub-id pub-id-type="doi">10.1242/jcs.01044</pub-id><pub-id pub-id-type="pmid">15039458</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jideama</surname><given-names>NM</given-names></name><name><surname>Noland</surname><given-names>TA</given-names><suffix>Jr</suffix></name><name><surname>Raynor</surname><given-names>RL</given-names></name><name><surname>Blobe</surname><given-names>GC</given-names></name><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Kazanietz</surname><given-names>MG</given-names></name><name><surname>Blumberg</surname><given-names>PM</given-names></name><name><surname>Hannun</surname><given-names>YA</given-names></name><name><surname>Kuo</surname><given-names>JF</given-names></name></person-group><article-title>Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>23277</fpage><lpage>23283</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.38.23277</pub-id><pub-id pub-id-type="pmid">8798526</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Solaro</surname><given-names>RJ</given-names></name></person-group><article-title>Calcium, thin filaments, and the integrative biology of cardiac contractility</article-title><source>Annu Rev Physiol</source><year>2005</year><volume>67</volume><fpage>39</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1146/annurev.physiol.67.040403.114025</pub-id><pub-id pub-id-type="pmid">15709952</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnsen</surname><given-names>DD</given-names></name><name><surname>Kacimi</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>BE</given-names></name><name><surname>Thomas</surname><given-names>TA</given-names></name><name><surname>Said</surname><given-names>S</given-names></name><name><surname>Gerdes</surname><given-names>AM</given-names></name></person-group><article-title>Protein kinase C isozymes in hypertension and hypertrophy: insight from SHHF rat hearts</article-title><source>Mol Cell Biochem</source><year>2005</year><volume>270</volume><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s11010-005-3781-x</pub-id><pub-id pub-id-type="pmid">15792354</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Walker</surname><given-names>LA</given-names></name><name><surname>Breemen</surname><given-names>RB</given-names></name><name><surname>Solaro</surname><given-names>RJ</given-names></name></person-group><article-title>A non-equilibrium isoelectric focusing method to determine states of phosphorylation of cardiac troponin I: identification of Ser-23 and Ser-24 as significant sites of phosphorylation by protein kinase C</article-title><source>J Mol Cell Cardiol</source><year>2005</year><volume>38</volume><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2004.10.014</pub-id><pub-id pub-id-type="pmid">15623438</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kr&#x000fc;ger</surname><given-names>M</given-names></name><name><surname>K&#x000f6;tter</surname><given-names>S</given-names></name><name><surname>Gr&#x000fc;tzner</surname><given-names>A</given-names></name><name><surname>Lang</surname><given-names>P</given-names></name><name><surname>Andresen</surname><given-names>C</given-names></name><name><surname>Redfield</surname><given-names>MM</given-names></name><name><surname>Butt</surname><given-names>E</given-names></name><name><surname>dos Remedios</surname><given-names>C</given-names></name><name><surname>Linke</surname><given-names>WA</given-names></name></person-group><article-title>Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs</article-title><source>Circ Res</source><year>2009</year><volume>104</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.184408</pub-id><pub-id pub-id-type="pmid">19023132</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linke</surname><given-names>WA</given-names></name></person-group><article-title>Sense and stretchiability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction</article-title><source>Cardiovasc Res</source><year>2008</year><volume>77</volume><fpage>637</fpage><lpage>648</lpage><pub-id pub-id-type="pmid">17475230</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marston</surname><given-names>SB</given-names></name><name><surname>Tombe</surname><given-names>PP</given-names></name></person-group><article-title>Troponin phosphorylation and myofilament Ca<sup>2+</sup>- sensitivity in heart failure: Increased or decreased?</article-title><source>J Mol Cell Cardiol</source><year>2008</year><volume>45</volume><fpage>603</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2008.07.004</pub-id><pub-id pub-id-type="pmid">18691597</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>AS</given-names></name><name><surname>Dignam</surname><given-names>JD</given-names></name><name><surname>Schlender</surname><given-names>KK</given-names></name></person-group><article-title>Cardiac myosin-binding protein C (MyBP-C): identification of protein kinase A and protein kinase C phosphorylation sites</article-title><source>Arch Biochem Biophys</source><year>1998</year><volume>358</volume><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1006/abbi.1998.0857</pub-id><pub-id pub-id-type="pmid">9784245</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moln&#x000e1;r</surname><given-names>A</given-names></name><name><surname>Borb&#x000e9;ly</surname><given-names>A</given-names></name><name><surname>Czuriga</surname><given-names>D</given-names></name><name><surname>Ivetta</surname><given-names>SM</given-names></name><name><surname>Szil&#x000e1;gyi</surname><given-names>S</given-names></name><name><surname>Hertelendi</surname><given-names>Z</given-names></name><name><surname>P&#x000e1;sztor</surname><given-names>ET</given-names></name><name><surname>Galajda</surname><given-names>Z</given-names></name><name><surname>Szerafin</surname><given-names>T</given-names></name><name><surname>Jaquet</surname><given-names>K</given-names></name><name><surname>Papp</surname><given-names>Z</given-names></name><name><surname>&#x000c9;des</surname><given-names>I</given-names></name><name><surname>T&#x000f3;th</surname><given-names>A</given-names></name></person-group><article-title>Protein kinase C contributes to the maintenance of contractile force in human ventricular cardiomyocytes</article-title><source>J Biol Chem</source><year>2008</year><volume>284</volume><fpage>1031</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1074/jbc.M807600200</pub-id><pub-id pub-id-type="pmid">18854307</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>DE</given-names></name><name><surname>Chandra</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Solaro</surname><given-names>RJ</given-names></name></person-group><article-title>Transgenic incorporation of skeletal TnT into cardiac myofilaments blunts PKC-mediated depression of force</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2001</year><volume>280</volume><fpage>H1011</fpage><lpage>H1018</lpage><pub-id pub-id-type="pmid">11179042</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morano</surname><given-names>I</given-names></name><name><surname>Arndt</surname><given-names>H</given-names></name><name><surname>Gartner</surname><given-names>C</given-names></name><name><surname>Reugg</surname><given-names>JC</given-names></name></person-group><article-title>Skinned fibers of human atrium and ventricle: myosin isozymes and contractility</article-title><source>Circ Res</source><year>1988</year><volume>62</volume><fpage>632</fpage><lpage>639</lpage><pub-id pub-id-type="pmid">3342480</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narolska</surname><given-names>NA</given-names></name><name><surname>Piroddi</surname><given-names>N</given-names></name><name><surname>Belus</surname><given-names>A</given-names></name><name><surname>Boontje</surname><given-names>NM</given-names></name><name><surname>Scellini</surname><given-names>B</given-names></name><name><surname>Deppermann</surname><given-names>S</given-names></name><name><surname>Zaremba</surname><given-names>R</given-names></name><name><surname>Musters</surname><given-names>RJ</given-names></name><name><surname>dos Remedios</surname><given-names>C</given-names></name><name><surname>Jaquet</surname><given-names>K</given-names></name><name><surname>Foster</surname><given-names>DB</given-names></name><name><surname>Murphy</surname><given-names>AM</given-names></name><name><surname>Eyk</surname><given-names>JE</given-names></name><name><surname>Tesi</surname><given-names>C</given-names></name><name><surname>Poggesi</surname><given-names>C</given-names></name><name><surname>Velden</surname><given-names>J</given-names></name><name><surname>Stienen</surname><given-names>GJ</given-names></name></person-group><article-title>Impaired diastolic function after exchange of endogenous troponin I with C-terminal truncated troponin I in human cardiac muscle</article-title><source>Circ Res</source><year>2006</year><volume>99</volume><fpage>1012</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000248753.30340.af</pub-id><pub-id pub-id-type="pmid">17023673</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Hunlich</surname><given-names>M</given-names></name><name><surname>Camp</surname><given-names>PC</given-names></name><name><surname>Begin</surname><given-names>KJ</given-names></name><name><surname>El-Zaru</surname><given-names>M</given-names></name><name><surname>Patten</surname><given-names>R</given-names></name><name><surname>Leavitt</surname><given-names>BJ</given-names></name><name><surname>Ittleman</surname><given-names>FP</given-names></name><name><surname>Alpert</surname><given-names>NR</given-names></name><name><surname>LeWinter</surname><given-names>MM</given-names></name><name><surname>VanBuren</surname><given-names>P</given-names></name></person-group><article-title>Thin filament-based modulation of contractile performance in human heart failure</article-title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>982</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000139334.43109.F9</pub-id><pub-id pub-id-type="pmid">15302786</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noland</surname><given-names>TA</given-names></name><name><surname>Raynor</surname><given-names>RL</given-names></name><name><surname>Kuo</surname><given-names>JF</given-names></name></person-group><article-title>Identification of sites phosphorylated in bovine cardiac troponin I and troponin T by protein kinase C and comparative substrate activity of synthetic peptides containing the phosphorylation sites</article-title><source>J Biol Chem</source><year>1989</year><volume>264</volume><fpage>20778</fpage><lpage>20785</lpage><pub-id pub-id-type="pmid">2584239</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathak</surname><given-names>A</given-names></name><name><surname>del Monte</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Schultz</surname><given-names>JE</given-names></name><name><surname>Lorenz</surname><given-names>JN</given-names></name><name><surname>Bodi</surname><given-names>I</given-names></name><name><surname>Weiser</surname><given-names>D</given-names></name><name><surname>Hahn</surname><given-names>H</given-names></name><name><surname>Carr</surname><given-names>AN</given-names></name><name><surname>Syed</surname><given-names>F</given-names></name><name><surname>Mavila</surname><given-names>N</given-names></name><name><surname>Jha</surname><given-names>L</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Marreez</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>McGraw</surname><given-names>DW</given-names></name><name><surname>Heist</surname><given-names>EK</given-names></name><name><surname>Guerrero</surname><given-names>JL</given-names></name><name><surname>DePaoli-Roach</surname><given-names>AA</given-names></name><name><surname>Hajjar</surname><given-names>RJ</given-names></name><name><surname>Kranias</surname><given-names>EG</given-names></name></person-group><article-title>Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase1</article-title><source>Circ Res</source><year>2005</year><volume>96</volume><fpage>756</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000161256.85833.fa</pub-id><pub-id pub-id-type="pmid">15746443</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solaro</surname><given-names>RJ</given-names></name><name><surname>Rosevear</surname><given-names>P</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name></person-group><article-title>The unique functions of cardiac troponin I in the control of cardiac muscle contraction and relaxation</article-title><source>Biochem Biophys Res Commun</source><year>2008</year><volume>369</volume><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.12.114</pub-id><pub-id pub-id-type="pmid">18162178</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumandea</surname><given-names>MP</given-names></name><name><surname>Pyle</surname><given-names>WG</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Tombe</surname><given-names>PP</given-names></name><name><surname>Solaro</surname><given-names>RJ</given-names></name></person-group><article-title>Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>35135</fpage><lpage>35144</lpage><pub-id pub-id-type="doi">10.1074/jbc.M306325200</pub-id><pub-id pub-id-type="pmid">12832403</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swiderek</surname><given-names>K</given-names></name><name><surname>Jaquet</surname><given-names>K</given-names></name><name><surname>Meyer</surname><given-names>HE</given-names></name><name><surname>Sch&#x000e4;chtele</surname><given-names>C</given-names></name><name><surname>Hofmann</surname><given-names>F</given-names></name><name><surname>Heilmeyer</surname><given-names>LM</given-names><suffix>Jr</suffix></name></person-group><article-title>Sites phosphorylated in bovine cardiac troponin T and I. Characterization by 31P-NMR spectroscopy and phosphorylation by protein kinases</article-title><source>Eur J Biochem</source><year>1990</year><volume>190</volume><fpage>575</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1990.tb15612.x</pub-id><pub-id pub-id-type="pmid">2373082</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velden</surname><given-names>J</given-names></name><name><surname>Narolska</surname><given-names>NA</given-names></name><name><surname>Lamberts</surname><given-names>RR</given-names></name><name><surname>Boontje</surname><given-names>NM</given-names></name><name><surname>Borb&#x000e9;ly</surname><given-names>A</given-names></name><name><surname>Zaremba</surname><given-names>R</given-names></name><name><surname>Bronzwaer</surname><given-names>JG</given-names></name><name><surname>Papp</surname><given-names>Z</given-names></name><name><surname>Jaquet</surname><given-names>K</given-names></name><name><surname>Paulus</surname><given-names>WJ</given-names></name><name><surname>Stienen</surname><given-names>GJM</given-names></name></person-group><article-title>Functional effects of protein kinase C-mediated myofilament phosphorylation in human myocardium</article-title><source>Cardiovasc Res</source><year>2006</year><volume>69</volume><fpage>876</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2005.11.021</pub-id><pub-id pub-id-type="pmid">16376870</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velden</surname><given-names>J</given-names></name><name><surname>Papp</surname><given-names>Z</given-names></name><name><surname>Boontje</surname><given-names>NM</given-names></name><name><surname>Zaremba</surname><given-names>R</given-names></name><name><surname>Jong</surname><given-names>JW</given-names></name><name><surname>Janssen</surname><given-names>PML</given-names></name><name><surname>Hasenfuss</surname><given-names>G</given-names></name><name><surname>Stienen</surname><given-names>GJM</given-names></name></person-group><article-title>The effect of myosin light chain 2 dephosphorylation on Ca<sup>2+</sup>-sensitivity of force is enhanced in failing human hearts</article-title><source>Cardiovasc Res</source><year>2003</year><volume>57</volume><fpage>505</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(02)00662-4</pub-id><pub-id pub-id-type="pmid">12566123</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velden</surname><given-names>J</given-names></name><name><surname>Papp</surname><given-names>Z</given-names></name><name><surname>Zaremba</surname><given-names>R</given-names></name><name><surname>Boontje</surname><given-names>NM</given-names></name><name><surname>Jong</surname><given-names>JW</given-names></name><name><surname>Owen</surname><given-names>VJ</given-names></name><name><surname>Burton</surname><given-names>PB</given-names></name><name><surname>Goldmann</surname><given-names>P</given-names></name><name><surname>Jaquet</surname><given-names>K</given-names></name><name><surname>Stienen</surname><given-names>GJM</given-names></name></person-group><article-title>Increased Ca<sup>2+</sup>-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins</article-title><source>Cardiovasc Res</source><year>2003</year><volume>57</volume><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(02)00606-5</pub-id><pub-id pub-id-type="pmid">12504812</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verduyn</surname><given-names>SC</given-names></name><name><surname>Zaremba</surname><given-names>R</given-names></name><name><surname>Velden</surname><given-names>J</given-names></name><name><surname>Stienen</surname><given-names>GJM</given-names></name></person-group><article-title>Effects of contractile protein phosphorylation on force development in permeabilized rat cardiac myocytes</article-title><source>Basic Res Cardiol</source><year>2007</year><volume>102</volume><fpage>476</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1007/s00395-007-0663-2</pub-id><pub-id pub-id-type="pmid">17546528</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Grant</surname><given-names>JE</given-names></name><name><surname>Doede</surname><given-names>CM</given-names></name><name><surname>Sadayappan</surname><given-names>S</given-names></name><name><surname>Robbins</surname><given-names>J</given-names></name><name><surname>Walker</surname><given-names>JW</given-names></name></person-group><article-title>PKC-betaII sensitizes cardiac myofilaments to Ca<sup>2+</sup> by phosphorylating troponin I on threonine-144</article-title><source>J Mol Cell Cardiol</source><year>2006</year><volume>41</volume><fpage>823</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2006.08.016</pub-id><pub-id pub-id-type="pmid">17010989</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>C</given-names></name><name><surname>Solaro</surname><given-names>RJ</given-names></name><name><surname>Buttrick</surname><given-names>PM</given-names></name></person-group><article-title>PKC&#x003b5; increases phosphorylation of the cardiac myosin binding protein C at serine 302 both in vitro and in vivo</article-title><source>Biochemistry</source><year>2007</year><volume>46</volume><fpage>7054</fpage><lpage>7061</lpage><pub-id pub-id-type="doi">10.1021/bi700467k</pub-id><pub-id pub-id-type="pmid">17503784</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamasaki</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>McNabb</surname><given-names>M</given-names></name><name><surname>Greaser</surname><given-names>M</given-names></name><name><surname>Labeit</surname><given-names>S</given-names></name><name><surname>Granzier</surname><given-names>H</given-names></name></person-group><article-title>Protein kinase A phosphorylates titin&#x02019;s cardiac-specific N2B domain and reduces passive tension in rat cardiac myocytes</article-title><source>Circ Res</source><year>2002</year><volume>90</volume><fpage>1181</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000021115.24712.99</pub-id><pub-id pub-id-type="pmid">12065321</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zabrouskov</surname><given-names>V</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Schwartz</surname><given-names>J</given-names></name><name><surname>Walker</surname><given-names>JW</given-names></name></person-group><article-title>Unraveling molecular complexity of phosphorylated human cardiac troponin I by top down electron capture dissociation/electron transfer dissociation mass spectrometry</article-title><source>Moll Cell Proteomics</source><year>2008</year><volume>7</volume><fpage>1838</fpage><lpage>1849</lpage><pub-id pub-id-type="doi">10.1074/mcp.M700524-MCP200</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaremba</surname><given-names>R</given-names></name><name><surname>Merkus</surname><given-names>D</given-names></name><name><surname>Hamdani</surname><given-names>N</given-names></name><name><surname>Lamers</surname><given-names>JMJ</given-names></name><name><surname>Paulus</surname><given-names>WJ</given-names></name><name><surname>dos Remedios</surname><given-names>C</given-names></name><name><surname>Duncker</surname><given-names>DJ</given-names></name><name><surname>Stienen</surname><given-names>GJM</given-names></name><name><surname>Velden</surname><given-names>J</given-names></name></person-group><article-title>Quantitative analysis of myofilament protein phosphorylation in small cardiac biopsies</article-title><source>Proteomics Clin Appl</source><year>2007</year><volume>1</volume><fpage>1285</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1002/prca.200600891</pub-id></mixed-citation></ref></ref-list></back></article>